The diagnostics firm cites 48% year-over-year growth in Q1 2026 revenue, driven by higher Shield test volumes.
Guardant Health increased its 2026 revenue outlook to a range of $1.30 billion to $1.32 billion, up from prior guidance. The company reported $302 million in Q1 2026 revenue, reflecting 48% growth compared to the same period last year.
The revised forecast follows strong demand for its Shield blood-based colorectal cancer test, with targets set at 230,000 to 245,000 tests for the year. Management attributed the growth to expanding commercial adoption and operational momentum.
Shares of Guardant Health rose in after-hours trading as investors reacted to the upward revision and robust quarterly performance.